Previous 10 | Next 10 |
Atossa Therapeutics press release ( NASDAQ: ATOS ): Q2 GAAP EPS of -$0.05. Total operating expenses were $6,595 for the three months ended June 30, 2022, which is a decrease of $409 or 6%, from the three months ended June 30, 2021, of $7,004. C...
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financia...
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COV...
Atossa Genetics (ATOS) Q2 Results Conference Call July 27, 2022 02:00 AM ET Company Participants Conference Call Participants Amit Harchandani - Citi Presentation Operator Thank you all for standing by and welcome to the Atossa First Half 2022...
ADP , AEP , ALIM , ALKS , APH , ASC , ATOS , AVY , BA , OTCQX:BASFY , BG , BMY , BSX , BXMT , CAMT , CCJ , CHEF , CME , COOP , CPG , CS , CSTM , OTCQX:DANOY , DB , EDU , EQNR , EVR ...
A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...
3 Tips for Buying Penny Stocks in June Buying penny stocks in 2022 is not easy. But, with the right research on hand and a keen eye for detail, it could be a profitable endeavor. Here are some things to keep in mind when looking for the best penny stocks to buy . For starters al...
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast ca...
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast can...
Atossa Therapeutics press release (NASDAQ:ATOS): Q1 GAAP EPS of -$0.04 beats by $0.02. As of March 31, 2022, the company had cash, cash equivalents and restricted cash of approximately $131,596. The company has no source of sustainable revenue and no associated cost of revenue. For further ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...